312 related articles for article (PubMed ID: 24681847)
1. The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Fallon J; Tighe R; Kradjian G; Guzman W; Bernhardt A; Neuteboom B; Lan Y; Sabzevari H; Schlom J; Greiner JW
Oncotarget; 2014 Apr; 5(7):1869-84. PubMed ID: 24681847
[TBL] [Abstract][Full Text] [Related]
2. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.
Paoloni M; Mazcko C; Selting K; Lana S; Barber L; Phillips J; Skorupski K; Vail D; Wilson H; Biller B; Avery A; Kiupel M; LeBlanc A; Bernhardt A; Brunkhorst B; Tighe R; Khanna C
PLoS One; 2015; 10(6):e0129954. PubMed ID: 26091536
[TBL] [Abstract][Full Text] [Related]
3. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.
Fallon JK; Vandeveer AJ; Schlom J; Greiner JW
Oncotarget; 2017 Mar; 8(13):20558-20571. PubMed ID: 28423552
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
6. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models.
Lo KM; Lan Y; Lauder S; Zhang J; Brunkhorst B; Qin G; Verma R; Courtenay-Luck N; Gillies SD
Cancer Immunol Immunother; 2007 Apr; 56(4):447-57. PubMed ID: 16874486
[TBL] [Abstract][Full Text] [Related]
7. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.
Morillon YM; Su Z; Schlom J; Greiner JW
J Immunother Cancer; 2019 Jun; 7(1):150. PubMed ID: 31186063
[TBL] [Abstract][Full Text] [Related]
8. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
9. NHS-IL12, a Tumor-Targeting Immunocytokine.
Greiner JW; Morillon YM; Schlom J
Immunotargets Ther; 2021; 10():155-169. PubMed ID: 34079772
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
11. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.
Strauss J; Heery CR; Kim JW; Jochems C; Donahue RN; Montgomery AS; McMahon S; Lamping E; Marté JL; Madan RA; Bilusic M; Silver MR; Bertotti E; Schlom J; Gulley JL
Clin Cancer Res; 2019 Jan; 25(1):99-109. PubMed ID: 30131389
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine.
Minnar CM; Lui G; Gulley JL; Schlom J; Gameiro SR
Front Oncol; 2023; 13():1321318. PubMed ID: 38260854
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abstract] [Full Text] [Related]
14. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
[TBL] [Abstract][Full Text] [Related]
15. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
Farsaci B; Higgins JP; Hodge JW
Int J Cancer; 2012 Apr; 130(8):1948-59. PubMed ID: 21633954
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.
Gatti-Mays ME; Tschernia NP; Strauss J; Madan RA; Karzai FH; Bilusic M; Redman J; Sater HA; Floudas CS; Toney NJ; Donahue RN; Jochems C; Marté JL; Francis D; McMahon S; Lamping E; Cordes L; Schlom J; Gulley JL
Oncologist; 2023 Apr; 28(4):364-e217. PubMed ID: 36640137
[TBL] [Abstract][Full Text] [Related]
17. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
18. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.
Garnett CT; Schlom J; Hodge JW
Clin Cancer Res; 2008 Jun; 14(11):3536-44. PubMed ID: 18519787
[TBL] [Abstract][Full Text] [Related]
19. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
Farsaci B; Donahue RN; Coplin MA; Grenga I; Lepone LM; Molinolo AA; Hodge JW
Cancer Immunol Res; 2014 Nov; 2(11):1090-102. PubMed ID: 25092771
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
